Dr. Katherine D. Crew, MD, MS

Dr. Crew practices at Trustees of Columbia University in the City of New York in New York, New York.

Dr. Crew's NPI, 1427132836, was assigned on October 24, 2006. Dr. Crew graduated from Vagelos College of Physicians and Surgeons in 1999. Dr. Crew holds New York license 218922.

Dr. Crew's primary practice is Trustees of Columbia University in the City of New York, at 630 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 342-5155.

Dr. Crew's primary practice is Trustees of Columbia University in the City of New York in New York, New York. Dr. Crew is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Crew to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Crew practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Crew's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Crew's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists breast cancer among the conditions Dr. Crew treats.

CMS data shows 654 Medicare services from Dr. Crew across 4 procedure codes in 2024, for 176 Medicare patients. Medicare paid $46,674 for them. Every service was in an office.

CMS counts 176 Medicare patients who saw Dr. Crew in 2024. The largest group is 65 to 74, with 91 patients. 75% of them have cancer, and 67% have high cholesterol. 26% are also on Medicaid. Their average risk score is 1.25, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Crew's median patient age at 57, with 96% women.

In 2024, Dr. Crew wrote 208 Medicare Part D claims for 73 patients. 94% of them were for generic drugs. CMS names the drug for 166 of them, across 5 drugs with 11 or more claims each, at $7,140 in total drug cost. In 2023, CMS named 284 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Crew for performance year 2024, reported through an alternative payment model (APM). Dr. Crew accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Crew as offering telehealth.

Dmand AI links 181 papers to Dr. Crew, published from 2007 to 2025. 2021 was the busiest year, with 18. The most frequent topics are Breast Neoplasms, Chemotherapy, Adjuvant and Decision Support Techniques. Dr. Crew has published most often in Breast Cancer Res Treat. Dr. Crew's most frequent co-authors are Dawn Lauryn Hershman, MD, Meghna S. Trivedi, MD and Kevin M. Kalinsky, MD.

Dmand AI links Dr. Crew to 18 clinical trials, 7 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Breast Carcinoma In Situ. Columbia University sponsors the most, 8.

CMS Open Payments shows 4 general payments to Dr. Crew from 4 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 93% of the total. AstraZeneca Pharmaceuticals LP paid the most, $101.

Dr. Crew graduated from Vagelos College of Physicians and Surgeons in 1999. Dr. Crew is a member of ASCO.

Dr. Crew is in network with 15 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.